Plasma zinc status not an effective prognostic factor for hospitalized COVID-19 patients

NewsGuard 100/100 Score

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the causative agent of the coronavirus 2019 (COVID-19) pandemic, has been associated with mortality and morbidity within patients who develop cytokine releasing syndrome (CRS). Due to previous evidence suggesting that zinc deficiencies can lead to complications along with an impaired antiviral response, a group of international researchers has undertaken a prospective observational study to investigate this association further.

The researchers explored the association between the plasma zinc concentration as well as the development of CRS while observing the subsequent consequence of this in hospitalized COVID-19 patients.

A pre-print version of the paper is available on the medRxiv* server, while the article undergoes peer review.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The Study

The study undertaken by the researchers consisted of a single-center observational approach within a tertiary hospital within CUB-Hôpital Erasme, Brussels. The research included 139 adult patients who had PCR-confirmed coronavirus and were enrolled within 72 hours of being admitted to the hospital from May 2020 to November 2020.

In order to assess CRS, the presence and severity of COVID-19-associated hyperinflammatory syndrome (cHIS) was measured using a six-point clinical scale validated within the study. The clinical outcomes were measured after a 90 day period. The recorded data included the length of hospital stay, the incidence of mechanical ventilation, and mortality.

Significance of Zinc

Zinc is the second most abundant trace mineral found in humans, however, approximately 20% of the global population suffers from some sort of zinc deficiency.

The importance of zinc within health is wide-spanning, with this mineral being significant for wound healing, normal growth, and development and modulating the immune system, including antiviral responses. Zinc is an integral component that makes up approximately 10% of the human proteome and encompasses many crucial enzymes and transcriptional factors.

Additionally, zinc status is a critical factor for antiviral immunity. Those with zinc deficiencies are more likely to acquire viral infections such as HIV or hepatitis C. With chronic zinc deficiency, the production of pro-inflammatory cytokines increases, which subsequently affects the outcome of inflammatory and immune disorders and diseases.

The pre-print study mentions previous studies that provide evidence for zinc deficiency associated with lung-damaging complications such as acute respiratory distress syndrome while also confirming the impaired antiviral influence this mineral can also have.

Findings

The study uncovered an interesting development that included a vast majority of hospitalized COVID-19 patients being zinc deficient. However, while this was the case, there was a lack of evidence on zinc plasma concentration and COVID-19-associated hyperinflammatory syndrome, which was also true of mortality and morbidity outcomes.

Although the results of this study supported the association of CRS with severe infections from SARS-CoV-2 and subsequent mortality, there was a lack of solid evidence provided by the assessment of the COVID-19-associated hyperinflammatory syndrome (cHIS) score. This result differed from another study which was referred to in the article due to the reporting in the lack of evidence of this association.

The researchers of this paper support the finding of CRS association with severe COVID-19; however, they mention that this result was found despite the use of immunomodulatory or suppressive therapies provided to patients, which would work to reduce the risk of CRS, improving patient outcome but reducing the cHis score. This may have influenced the study results and the lack of significance of this association found.

The study concluded that this utilization of zinc concentrations as a prognostic factor is unreliable and not supported by the findings. Although, further research studies are encouraged to investigate the role of zinc as a biomarker to assess its reliability in predicting risks of developing tissue-damaging CRS and the subsequent outcomes in SARS-CoV-2 infected patients.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 10 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Marzia Khan

Written by

Marzia Khan

Marzia Khan is a lover of scientific research and innovation. She immerses herself in literature and novel therapeutics which she does through her position on the Royal Free Ethical Review Board. Marzia has a MSc in Nanotechnology and Regenerative Medicine as well as a BSc in Biomedical Sciences. She is currently working in the NHS and is engaging in a scientific innovation program.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Khan, Marzia. (2023, April 10). Plasma zinc status not an effective prognostic factor for hospitalized COVID-19 patients. News-Medical. Retrieved on April 19, 2024 from https://www.news-medical.net/news/20210614/Plasma-zinc-status-not-an-effective-prognostic-factor-for-hospitalized-COVID-19-patients.aspx.

  • MLA

    Khan, Marzia. "Plasma zinc status not an effective prognostic factor for hospitalized COVID-19 patients". News-Medical. 19 April 2024. <https://www.news-medical.net/news/20210614/Plasma-zinc-status-not-an-effective-prognostic-factor-for-hospitalized-COVID-19-patients.aspx>.

  • Chicago

    Khan, Marzia. "Plasma zinc status not an effective prognostic factor for hospitalized COVID-19 patients". News-Medical. https://www.news-medical.net/news/20210614/Plasma-zinc-status-not-an-effective-prognostic-factor-for-hospitalized-COVID-19-patients.aspx. (accessed April 19, 2024).

  • Harvard

    Khan, Marzia. 2023. Plasma zinc status not an effective prognostic factor for hospitalized COVID-19 patients. News-Medical, viewed 19 April 2024, https://www.news-medical.net/news/20210614/Plasma-zinc-status-not-an-effective-prognostic-factor-for-hospitalized-COVID-19-patients.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aging affects immune response and virus dynamics in COVID-19 patients, study finds